Brought to you by 
Sciele gets US rights to Plethora's PSD502; rights returned
08 Jun 2021
Executive Summary
Sciele Pharma (cardiovascular disease, women's health, and diabetes) has licensed exclusive US marketing rights to Plethora Solutions' (women's health and male sexual dysfunction) PSD502, a compound for premature ejaculation (PE) that will begin Phase III trials later this year.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sciele gets US rights to Plethora's PSD502; rights returned
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice